MEXTOVI(Binimetinib) Side Effects

Common adverse reactions include fatigue, nausea, and diarrhea; serious risks include cardiomyopathy and hemorrhage.

Adverse Reactions

The most frequently reported adverse reactions (≥25%) when combined with encorafenib include fatigue, nausea, diarrhea, vomiting, and abdominal pain in melanoma patients, with NSCLC patients additionally experiencing musculoskeletal pain, visual impairment, constipation, dyspnea, rash, and cough. Serious adverse reactions can include new primary malignancies (cutaneous and non-cutaneous), cardiomyopathy, venous thromboembolism, ocular toxicities such as serous retinopathy and retinal vein occlusion, hepatotoxicity, rhabdomyolysis, and hemorrhage.

MEXTOVI(Binimetinib)
Kinase inhibitor used in combination with encorafenib for the treatment of BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma, and BRAF V600E...
RELATED ARTICLES
/ 0
0 in total
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
Mailbox:Info@Lucius.La
Welcome To Consult
Ucius Pharmaceuticals (Lao) Co.,Ltd All Rights Reserved